Glenmark Pharmaceuticals makes it to the prestigious Dow Jones Sustainability Emerging Markets Index for the fourth consecutive year

16 Nov 2021 | Read More

Glenmark Pharma reports revenue growth of 6.6% and PAT growth of 10.1% YoY for Q2 FY 2021-22

12 Nov 2021 | Read More

Glenmark becomes the first company to launch Remogliflozin + Vildagliptin + Metformin fixed dose combination, at an affordable price for adults with Type 2 Diabetes in India

26 Oct 2021 | Read More

Glenmark launches Tavulus® for COPD treatment in Spain, becoming one of the first companies to launch a bioequivalent version of the dry powder inhaler

11 Oct 2021 | Read More

Glenmark receives marketing approval for Ryaltris®, an innovative combination nasal spray, in 13 countries across the EU and UK

30 Sep 2021 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Phosphate Foam, 1%

21 Sep 2021 | Read More

Glenmark concludes post marketing surveillance (PMS) study on Favipiravir (FabiFlu®) in 1000+ COVID-19 patients, findings reinforce the drug’s safety and efficacy in real world settings

15 Sep 2021 | Read More

Glenmark Pharma reports revenue growth of 26% and PAT growth of 21% YoY for Q1 FY 2021-22

13 Aug 2021 | Read More

Glenmark inks agreement with Canadian biotech SaNOtize to commercialize Nitric Oxide Nasal Spray for COVID-19 treatment in India and other Asian markets

2 Aug 2021 | Read More

Glenmark receives ANDA tentative approval for Nintedanib Capsules, 100 mg and 150 mg

25 Jun 2021 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Arformoterol Tartrate Inhalation Solution, 15 mcg/2 mL, Unit-Dose Vials

23 Jun 2021 | Read More

Glenmark launches Tiogiva®, becoming one of the first companies in the UK to launch a bioequivalent version of Tiotropium Bromide dry powder  inhaler

15 Jun 2021 | Read More

Glenmark releases interim data from PMS Study on Favipiravir

8 Jun 2021 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Theophylline Extended-Release Tablets, 300 mg and 450 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity on the 450 mg

4 Jun 2021 | Read More

Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg

1 Jun 2021 | Read More

Glenmark’s consolidated revenues grow 2.8% to Rs. 1,09,439 Mn in FY21

28 May 2021 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Icatibant Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe

24 May 2021 | Read More

Glenmark launches Ryaltris®-AZ at an affordable price in India

3 May 2021 | Read More

Glenmark’s Ryaltris ® nasal spray now approved in Europe for the first line treatment of allergic rhinitis in patients over 12 years of age

26 Apr 2021 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity.

24 Mar 2021 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Diltiazem Hydrochloride Extended-Release Capsules USP, 60 mg, 90 mg, and 120 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity

23 Mar 2021 | Read More

Glenmark and Bausch Health join together to commercialize RYALTRIS ™ nasal spray in Canada

22 Mar 2021 | Read More

Glenmark signs on Rohit Sharma as brand ambassador of Candid Powder

5 Mar 2021 | Read More

Glenmark receives ‘India Pharma Innovation of the Year’ Award from the Govt. of India

25 Feb 2021 | Read More

Glenmark’s Ryaltris®- innovative single nasal spray, ready to market in Russia

22 Feb 2021 | Read More

Glenmark launches SUTIB (Sunitinib) – priced 96% lower than the innovator brand. Reduces the risk of kidney cancer progression by 58%

16 Feb 2021 | Read More

 Glenmark’s consolidated sales rises by 3.88% to Rs. 27,605.07 Mn. in Q3 FY 2020-21

12 Feb 2021 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Phosphate Gel USP, 1%

11 Feb 2021 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg

3 Feb 2021 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Amphetamine Sulfate Tablets USP, 5 mg and 10 mg

28 Jan 2021 | Read More